Form 4: Veracyte Director Karin Eastham Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Karin Eastham exercised stock options and sold shares of Veracyte, Inc. under a pre-arranged 10b5-1 trading plan.
Summary
- Karin Eastham, a director at Veracyte, Inc., executed a stock option to acquire 10,000 shares of common stock at a price of $5.28 per share on January 2, 2025.
- On the same day, Eastham sold 5,309 shares at a weighted average price of $40.1224 per share, with individual sale prices ranging from $39.46 to $40.36.
- Additionally, Eastham sold 4,691 shares at a weighted average price of $40.5022 per share, with individual sale prices ranging from $40.37 to $40.78.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 20, 2024.
- Following these transactions, Eastham directly owns 18,497 shares of common stock.
Sentiment
Score: 5
Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.
Industry Context
This is a routine filing for insider transactions and is common for directors and officers of publicly traded companies. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a standard practice among corporate insiders to manage their stock transactions and avoid potential conflicts of interest.
- Similar filings are regularly made by directors and officers of other publicly traded companies such as Exact Sciences (EXAS) and Guardant Health (GH) when they exercise options or sell shares.
- The reported prices are within the typical range for market transactions of this type.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not indicate a change in the director's long-term view of the company.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date the Rule 10b5-1 plan was adopted by the reporting person. |
| 01/02/2025 | Date of stock option exercise and share sales. |
| 01/06/2025 | Date of signature on the Form 4 filing. |
| 06/20/2026 | Expiration date of the stock option. |
Keywords
Form 4, insider trading, stock options, share sales, Rule 10b5-1, Veracyte, VCYT, director, Karin Eastham
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.